Operating

Accrued liabilities

Bristol-Myers Squibb Accrued liabilities decreased by 45.7% to -$3.50B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 457.4%, from -$627.00M to -$3.50B.

Analysis

StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2019
Last reportedQ1 2026Apr 30, 2026

How to read this metric

An increase acts as a source of cash, suggesting deferred payments, while a decrease acts as a use of cash, indicating the settlement of accrued obligations.

Detailed definition

This represents the net change in short-term obligations that have been incurred but not yet paid, excluding standard ac...

Peer comparison

Standard working capital metric found in the operating section of the cash flow statement for all public companies.

Metric ID: operating_increase_decrease_in_other_accrued_liabilities

Historical Data

13 periods
 Q3 '21Q1 '22Q3 '22Q1 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$908.00M-$930.00M$1.14B-$910.00M$1.53B-$665.00M$735.00M$1.82B-$627.00M$881.00M$1.70B-$2.40B-$3.50B
QoQ Change-202.4%+222.6%-179.8%+268.5%-143.4%+210.5%+147.5%-134.5%+240.5%+93.3%-240.8%-45.7%
YoY Change+25.6%+2.2%+34.5%+26.9%+18.7%+5.7%+19.9%-6.4%-457.4%
Range-$3.50B$1.82B
CAGR+56.7%
Avg YoY Growth-36.7%
Median YoY Growth+18.7%
Current Streak2 quarters decline

Frequently Asked Questions

What is Bristol-Myers Squibb's accrued liabilities?
Bristol-Myers Squibb (BMY) reported accrued liabilities of -$3.50B in Q1 2026.
How has Bristol-Myers Squibb's accrued liabilities changed year-over-year?
Bristol-Myers Squibb's accrued liabilities decreased by 457.4% year-over-year, from -$627.00M to -$3.50B.
What does accrued liabilities mean?
The net change in short-term debts owed for services or expenses that have not yet been paid in cash.